Advertisement
| anti-egfr antibody therapy: Perioperative Chemotherapy U. Metzger, F. Largiader, H.-J. Senn, 2012-12-06 One reason for failure to cure solid tumors by surgery appears to be the impossibility of controlling metastases that are present but latent at the time of operation. This failure is a common clinical experience with aggressive neoplasms. but it is not always appreciated in tumors with longer survival times. e. g .• breast and colon cancer. In addition. recent evidence indicates that after resection of a primary tumor micrometas tases from it might be enhanced by suppression of immune and reticu loendothelial functions of the host. Other factors, such as increase of coagulability and stress in the perioperative period, can also promote tumor growth. The development of new metastases might be facilitated by cells forced into the circulation during operative manipulations. Such events could be important for the outcome of treatment and it is suggested that preventive measures should be directed to this systemic component of solid tumors. Radical surgery can reduce the number of tumor cells to a subclinical 3 6 stage (10 to 10 cells) in which chemotherapy might be more effective than in advanced stages. Chemotherapy, on the other hand, might aggravate the surgical morbidity by influencing the wound healing pro cess, by decreasing the immune response, and/or by toxicity to the bone marrow and to the gastrointestinal tract, for example. |
| anti-egfr antibody therapy: Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies Shi Hu, 2022-11-11 Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies presents a description of the sensitizers used to overcome resistance to anti-EGFR targeted antibody therapies in cancer, including novel engineered antibody drugs and other sensitizers. The book gives insights into the landscape of anti-EGFR based cancer treatments, the challenges of targeted therapy, and a glimpse into the future of antibody therapy. It offers pertinent science information on strategies used for the rational design and discovery of novel sensitizing agents, and in addition, translational studies involving pre-clinical and clinical design. This book is an indispensable resource for cancer researchers, medicinal chemists and other biomedical scientists.Finally, the book covers basic science strategies used in drug discovery and preclinical evaluation focused on EGFR blockage resistance, as well as clinical trial methodology, including clinical pharmacokinetics and imaging to address issues of efficacy evaluation of the new anticancer sensitizers for anti-EGFR drug resistance. - Presents detailed descriptions on the history, chemistry, mechanism of action, structure-function relationships, pharmacology, side effects, dosing and formulation of new sensitizers to anti-EGFR antibodies - Provides molecular structures for all novel anticancer drugs, along with strategies to overcome resistance to anti-EGFR antibodies - Encompasses up-to-date information on the cancer drug discovery process, including new research tools, tumor-targeting strategies, and fundamental concepts in emerging areas of precision medicine |
| anti-egfr antibody therapy: The Oncogenomics Handbook William J. LaRochelle, Richard A. Shimkets, 2007-11-09 An integrated overview of cancer drug discovery and development from the bench to the clinic, showing with broad strokes and representative examples the drug development process as a network of linked components leading from the discovered target to the ultimate therapeutic product. Following a systems biology approach, the authors explain genomic databases and how to discover oncological targets from them, how then to advance from the gene and transcript to the level of protein biochemistry, how next to move from the chemical realm to that of the living cell and, ultimately, pursue animal modeling and clinical development. Emerging cancer therapeutics including Ritux an, Erbitux, Gleevec Herceptin, Avastin, ABX-EGF, Velcade, Kepivance, Iressa, Tarceva, and Zevalin are addressed. Highlights include cancer genomics, pharmacogenomics, transcriptomics, gene expression analysis, proteomic and enzymatic cancer profiling technologies, and cellular and animal approaches to cancer target validation. |
| anti-egfr antibody therapy: Advances in the Molecular Understanding of Colorectal Cancer Eva Segelov, 2019-02-06 An understanding of the molecular pathogenesis of colorectal cancer by researchers and clinicians is essential to facilitate progress in improving patient outcomes in this common cancer that still carries a poor prognosis if not identified early. This book covers the major areas of importance in the field, incorporating new knowledge that has arisen due to the advancement of molecular techniques and the ability to correlate molecular changes with clinical behaviour of tumours. Each chapter is a summary written by experts, concisely summarising current data as well as highlighting potential areas for advancement. Appreciating the differences between tumours on a molecular level is the key to developing and delivering precision medicine, and nowhere is this more critically required than in the field of colorectal cancer. |
| anti-egfr antibody therapy: Safety of Biologics Therapy Brian A. Baldo, 2016-08-12 This long overdue title provides a comprehensive, up-to-date, state-of-the art review of approved biologic therapies, with coverage of mechanisms of action, Indications for therapy, immunogenicity and a detailed examination of adverse effects and safety of the many and diverse therapeutic agents presented in a total of 13 chapters. It is predicted that by 2016, biologics will make up half of the world's 20 top-selling drugs and by 2018, biologic medicine sales will account for almost half of the world's 100 biggest selling drugs. Recombinant proteins dominate the growing list of the more than 200 approved biotherapeutic agents with targeted antibodies, fusion proteins and receptors; cytokines; hormones; enzymes; proteins involved in blood-clotting, homeostasis and thrombosis; vaccines; botulinum neurotoxins; and, more recently, biosimilar preparations, comprising the majority of approved biologics. Written with clinicians, other health care professionals, and researchers in mind, Safety of Biologics Therapy examines, in a single volume, the full range of issues surrounding the safety of approved biologic therapies. A good understanding of the risks and safety issues of modern biologics therapy is increasingly being demanded of all those connected with their development, handling, prescribing, administration and subsequent patient management. In addition to being of great value to clinicians in all branches of medicine, and to nurses, pharmacists and researchers, this book will prove invaluable for students taking undergraduate and graduate courses in the above disciplines and in the biomedical sciences. |
| anti-egfr antibody therapy: Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies Chi Hin Cho, Tao Hu, 2020-05-27 Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies, Volume Eight, summarizes the molecular mechanisms of drug resistance in colorectal cancer, along with the most up-to-date therapeutic strategies available. The book discusses reasons why colorectal tumors become refractory during the progression of the disease, but also explains how drug resistance occurs during chemotherapy. In addition, users will find the current therapeutic strategies used by clinicians in their practice in treating colorectal cancer. The combination of conventional anticancer drugs with chemotherapy-sensitizing agents plays a pivotal role in improving the outcome of colorectal cancer patients, in particular those with drug-resistant cancer cells. From a clinical point-of-view, the content of this book provides clinicians with updated therapeutic strategies for a better choice of drugs for drug-resistant colorectal cancer patients. It will be a valuable source for cancer researchers, oncologists and several members of biomedical field who are dedicated to better treat patients with colorectal cancer. |
| anti-egfr antibody therapy: Handbook of Therapeutic Antibodies Stefan Dübel, Janice M. Reichert, 2014-12-03 Dieses Nachschlagewerk zu therapeutischen Antikörpern sucht auch in der komplett überarbeiteten 2. Auflage seinesgleichen und bietet 30 % neue Inhalte zu Entwicklung, Herstellung und therapeutischen Anwendungen dieser Biomoleküle. |
| anti-egfr antibody therapy: Dermatologic Principles and Practice in Oncology Mario E. Lacouture, 2013-11-26 The first book focusing specifically on frequent and frequently disabling side effects involving the skin, hair and nails in cancer patients According to the World Health Organization, there are approximately thirty million people living with a diagnosis of cancer – the majority of whom will receive surgery, systemic therapy, and/or radiation, and who will suffer from dermatologic adverse events. Dermatologists and oncologists are only beginning to grapple with these events, which pose serious quality-of-life issues with so many patients, and will become more prevalent as survival rates improve, thanks in part to new cancer treatments and drug regimens. Concentrating on a topic that has only been briefly touched upon by other texts, this book offers a focused perspective on the clinical presentation, underlying pathophysiologic mechanisms, and management of skin, hair, and nail conditions for oncologists, dermatologists, and allied practitioners. Dermatologic Principles and Practice in Oncology: Conditions of the Skin, Hair, and Nails in Cancer Patients: • Covers in detail the dermatologic adverse events of oncologic therapies, clinical presentations, and treatment recommendations • Enables dermatologists and other practitioners to significantly improve the care of patients with cancer • Addresses the dermatologic adverse events of cancer therapies used globally, of which a large number are found in developing countries • Emphasizes prophylactic measures – based on treatments used and type of cancer – to prevent the appearance of adverse events • Provides built-in discussions on patient education for practical counseling during therapies • Offers rapid-reference sections on topical dermatology drugs The first book to present dermatologic conditions in cancer patients and survivors in a uniform and in-depth manner, Dermatologic Principles and Practice in Oncology is ideal for oncologists, oncology nurses, and dermatologists who wish to take better care of those with adverse skin, hair, and nail conditions. |
| anti-egfr antibody therapy: Inpatient Dermatology Misha Rosenbach, Karolyn A. Wanat, Robert G. Micheletti, Laura A. Taylor, 2018-11-03 Inpatient Dermatology is a concise and portable resource that synthesizes the most essential material to help physicians with recognition, differential diagnosis, work-up, and treatment of dermatologic issues in the hospitalized patient. Complete with hundreds of clinical and pathologic images, this volume is both an inpatient dermatology atlas and a practical guide to day-one, initial work-up, and management plan for common and rare skin diseases that occur in the inpatient setting. Each chapter is a bulleted, easy-to-read reference that focuses on one specific inpatient dermatologic condition, with carefully curated clinical photographs and corresponding histopathologic images to aid readers in developing clinical-pathologic correlation for the dermatologic diseases encountered in the hospital. Before each subsection the editors share diagnostic pearls, explaining their approach to these challenging conditions. This book is structured to be useful to physicians, residents, and medical students. It spans dermatology, emergency medicine, internal medicine, infectious disease, and rheumatology. Inpatient Dermatology is the go-to guide for hospital-based skin diseases, making even the most complex inpatient dermatologic issues approachable and understandable for any clinician. |
| anti-egfr antibody therapy: Protein Therapeutics Tristan Vaughan, Jane Osbourn, Bahija Jallal, 2017-08-02 In this practice-oriented two volume handbook, professionals from some of the largest biopharmaceutical companies and top academic researchers address the key concepts and challenges in the development of protein pharmaceuticals for medicinal chemists and drug developers of all trades. Following an introduction tracing the rapid development of the protein therapeutics market over the last decade, all currently used therapeutic protein scaffolds are surveyed, from human and non-human antibodies to antibody mimetics, bispecific antibodies and antibody-drug conjugates. This ready reference then goes on to review other key aspects such as pharmacokinetics, safety and immunogenicity, manufacture, formulation and delivery. The handbook then takes a look at current key clinical applications for protein therapeutics, from respiratory and inflammation to oncology and immune-oncology, infectious diseases and rescue therapy. Finally, several exciting prospects for the future of protein therapeutics are highlighted and discussed. |
| anti-egfr antibody therapy: Innovations for Next-Generation Antibody-Drug Conjugates Marc Damelin, 2018-05-29 Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients. |
| anti-egfr antibody therapy: Immunotherapy for Gastrointestinal Cancer David Kerr, Rebecca Johnson, 2017-01-02 This book is about the manipulation of the immune system as a therapeutic approach to gastrointestinal cancer and its clinical applications, exploring therapeutic approaches which might be taken under the broad banner of immunotherapy. Starting by introducing concepts of modern immunology, the clinical applications of immunotherapy are then discussed. The reader will learn about the three broad classes of immune therapeutic agents: cell-based treatment; antibody therapy; cytokine application and the key effector cells and mechanisms which might cause tumour rejection. The reverse side of this equation, the genetic and molecular mechanisms which the tumour can use to escape immune control and regulation, is also discussed. Through reviewing the most up-to-date evidence, this volume provides an overview of the important scientific lessons learned from past failure of immunotherapeutics in the clinic and highlights more positive recent data, coupled to practical guidelines for clinical usage. Written by a team of worldwide experts, this is an indispensable guide for medical oncologists, surgical oncologists, radiation therapists, pharmacists, oncology nurse specialists. |
| anti-egfr antibody therapy: Drug-Induced Liver Injury , 2019-07-13 Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series |
| anti-egfr antibody therapy: Current Therapy In Oral and Maxillofacial Surgery Shahrokh C. Bagheri, Bryan Bell, Husain Ali Khan, 2011-09-19 Written by expert surgeons and educators, Current Therapy in Oral and Maxillofacial Surgery covers the latest treatment strategies, surgical techniques, and potential complications in OMS. Emphasizing an evidence-based approach, it covers all 12 subspecialties of OMS, addressing topics from surgical principles to oral surgery, anesthesia, cranio-maxillofacial trauma surgery, head and neck surgery, maxillofacial reconstructive surgery, orthognathic surgery, pediatric craniofacial surgery including cleft lip and palate, temporomandibular joint disorders, facial plastic surgery including rhinoplasty and facelifts, obstructive sleep apnea, and oral and maxillofacial infections. At the end of each chapter, Pearls and Pitfalls summarize the authors' insight, recommendations, and experience on that topic. Editor Dr. Shahrokh Bagheri is a noted professor, researcher, and speaker on OMS, and he leads an expert author team including Dr. R. Bryan Bell and Dr. Husain Ali Khan to help you master and apply the latest advances in OMS. More than 1,200 full-color photos and 200 color line drawings illustrate concepts and provide visual guidance in clinical areas. Comprehensive sections and chapters represent essential topics, the newest advances, and controversial topics. Clinical coverage brings together the latest knowledge in OMS in a concise, easy-to-apply way. Resident-specific coverage describes the wide array of subspecialties and treatments available in the armamentarium of the modern OMS. A focus on complications ensures that you are knowledgeable in this important part of any therapy or surgical discipline. Expert contributors include the best of the best, featuring leading, well-established, and respected surgeons and educators writing on their areas of specialty and providing current treatment strategies. |
| anti-egfr antibody therapy: Immunologic Concepts in Transfusion Medicine Robert W Maitta, 2019-08-27 Immunological Concepts in Transfusion Medicine provides a thorough discussion of the immune aspects of blood component transfusion, with in-depth information on the intricacies of immune responses to blood components and the immune processes that may be initiated in response to blood exposure. Written to increase knowledge and awareness of immune challenges such as alloimmunization and transfusion-related acute lung injury, this title bridges current basic scientific discoveries and the potential effects seen in blood recipients. - Complies the knowledge and expertise of Dr. Robert Maitta, an expert in immune responses and antibody function/structure studies. - Helps clinicians in the daily practice of caring for patients in need of transfusion support, as well as physicians in training when considering utilizing blood transfusions in a limited scope or in the setting of massive transfusion. - Includes an immunology primer as an introduction to in-depth chapters covering allergic immune reactions to blood components, transfusion-related immunomodulation, fetal and neonatal alloimmune thrombocytopenia and neonatal neuthropenia, complications of haploidentical and mismatched HSC transplantation, chimeric antibody receptor therapies, and much more. - Consolidates today's available information on this timely topic into a single, convenient resource. |
| anti-egfr antibody therapy: Elsevier's 2022 Intravenous Medications - E-Book Shelly Rainforth Collins, 2021-04-16 Find the essential information you need to safely administer more than 400 intravenous drugs! For more than 45 years, Gahart’s Intravenous Medications: A Handbook for Nurses and Health Professionals has been a trusted resource for comprehensive drug coverage, unparalleled accuracy, and an intuitive quick-access format. In addition to updated drug interactions, precautions, alerts, and patient teaching instructions for all existing IV drugs, the 2022 edition includes approximately 10 new monographs of the most recent IV drugs to be approved by the FDA. Administering intravenous drugs is a critical task — inaccurate or out-of-date information is not an option. Known as the #1 IV drug handbook on the market, and with its history of impeccable accuracy, Gahart’s annual publication gives you the extra confidence and guidance you need to safely and effectively treat patients. Monographs on more than 400 IV drugs offer an impressive breadth of coverage that goes well beyond any comparable drug reference. Updated annual publication prevents you from referencing outdated information. Additional drug monographs are provided on the companion Evolve website. 45-year history of impeccable accuracy reinforces the importance of safe IV drug administration. Perfect depth of information equips you with everything that is needed for safe administration of IV drugs — nothing more, nothing less. Proven, clinically optimized format keeps all dosage information for each drug on either a single page or a two-page spread to prevent hand contamination by having to turn a page. Highlighted Black Box Warnings and relevant content make locating critical information fast and easy. Special circumstances in blue-screened text call attention to important circumstances that may not warrant Black Box Warnings. Life-stage dosage variances are highlighted for geriatric, pediatric, infant, and neonatal patients. Dilution and dosage charts within monographs provide quick access to essential clinical information. Convenient, alphabetical format organizes all drug monographs by generic name, allowing you to find any drug in seconds. NEW! Drug monographs for newly approved drugs by the FDA provide you with the most current drug information. Updates on drug interactions, precautions, alerts, and more have been made throughout the guide to reflect all changes to existing medications. |
| anti-egfr antibody therapy: Molecular and Cellular Changes in the Cancer Cell , 2016-11-16 Molecular and Cellular Changes in the Cancer Cell,the latest volume in the Progress in Molecular Biology and Translational Science series, includes a comprehensive summary of the evidence accumulated thus far on the molecular and cellular regulation of the various adaptations taking place in response to exercise. This volume examines some of the latest advances, highlighting some of the most important molecular and cellular alterations and environmental influences that collectively cause a normal cell to become cancerous. Special emphasis is given to changes that take place at the molecular and cellular level. Comprehensive and up-to-date survey of current knowledge on the cancer cell Includes the latest advances and the most important molecular and cellular alterations and environmental influences collectively causing cells to become cancerous Written by leading experts in the field |
| anti-egfr antibody therapy: Antibody Fusion Proteins Steven M. Chamow, Avi Ashkenazi, 1999-04-13 Thoroughly detailed and illustrated, this book examines the construction, properties, applications, and problems associated with specific types of fusion molecules used in clinical and research medicine. The editors present an overview of the field, followed by nine chapters divided into two general sections based on the two primary parts of the antibody molecule: Fab fusion proteins and Fc fusion proteins. In addition, numerous renowned scientists in the field have contributed outlines demonstrating man-made molecules that will be required not only to overcome the limitations of monoclonal antibodies, but also to extend the principle of selective targeting. Divided into specific, accessible sections, Antibody Fusion Proteins includes: * Chapters describing Fc fusion proteins, as well as several classes of antigen-binding proteins * Complete details on the design and molecular construction of genetically engineered fusion molecules * Useful information on molecular purification, large-scale production, practical applications, and their therapeutic potential * The latest data on forming fusion proteins with toxins, cytokines, or enzymes that can activate a prodrug |
| anti-egfr antibody therapy: Cancer Signaling Christoph Wagener, Carol Stocking, Oliver Müller, 2016-08-12 Cancer, which has become the second-most prevalent health issue globally, is essentially a malfunction of cell signaling. Understanding how the intricate signaling networks of cells and tissues allow cancer to thrive - and how they can be turned into potent weapons against it - is the key to managing cancer in the clinic and improving the outcome of cancer therapies. In their ground-breaking textbook, the authors provide a compelling story of how cancer works on the molecular level, and how targeted therapies using kinase inhibitors and other modulators of signaling pathways can contain and eventually cure it. The first part of the book gives an introduction into the cell and molecular biology of cancer, focusing on the key mechanisms of cancer formation. The second part of the book introduces the main signaling transduction mechanisms responsible for carcinogenesis and compares their function in healthy versus cancer cells. In contrast to the complexity of its topic, the text is easy to read. 32 specially prepared teaching videos on key concepts and pathways in cancer signaling are available online for users of the print edition and have been integrated into the text in the enhanced e-book edition. |
| anti-egfr antibody therapy: Infectious Complications in Cancer Patients Valentina Stosor, Teresa R. Zembower, 2014-04-05 While advances in both the treatment of cancer and the management of its complications have led to significant improvement in patient survival, infections remain a significant cause of morbidity and mortality in patients with neo plastic disease. In this patient population, infection risk results from a complex interplay between the host’s underlying immunodeficiencies, local tumor effects and treatment-induced immunosuppression. New chemotherapeutic approaches and antimicrobial prophylaxis and treatment practices continue to shape the spectrum of infections in these patients. Clinicians who treat infections in cancer patients are continually challenged by the emergence of new pathogens and by the increasing antimicrobial resistance of established ones. The aim of this book is to emphasize unique aspects of management of infectious diseases in the cancer patient. With the increasing complexity of this patient population, optimal management requires a multidisciplinary approach and this fact is fully reflected in the contributions, all from recognized authorities in the field. Ultimately, it is hoped that this volume will assist specialists in infectious diseases and haematology/oncology in the diagnosis, management and prevention of infection and optimization of the overall care of patients with malignancies. |
| anti-egfr antibody therapy: Physiologic and Pathologic Angiogenesis Dan Simionescu, Agneta Simionescu, 2017-04-05 The purpose of this book is to highlight novel advances in the field and to incentivize scientists from a variety of fields to pursue angiogenesis as a research avenue. Blood vessel formation and maturation to capillaries, arteries, or veins is a fascinating area which can appeal to multiple scientists, students, and professors alike. Angiogenesis is relevant to medicine, engineering, pharmacology, and pathology and to the many patients suffering from blood vessel diseases and cancer, among others. We are hoping that this book will become a source of inspiration and novel ideas for all. |
| anti-egfr antibody therapy: Oral Precancer Peter Thomson, 2012-04-23 Without early detection, oral cancer is deadly. Protect your patients by applying the latest clinical interventions. Rates of new oral cancer cases continue to increase and mortality rates remain alarmingly high. Oral cancer may be preceded by clinically identifiable precancerous changes in the oral mucosa, which offer a therapeutic window of opportunity to intervene and halt disease progression to carcinoma development. Written and edited by prominent researchers in the field, Oral Precancer: Reviews current scientific research on precancer conditions of the oral cavity providing evidence-based analysis of the nature and behavior of potentially malignant and deforming oral diseases Explains the principles of prevention, diagnosis and management of potentially malignant disorders of the oral cavity Details a practical and reliable interventional treatment strategy to facilitate early diagnosis and effective treatment of both precancer and early invasive carcinoma Contains a chapter devoted to illustrative case histories, high-quality, color, clinical photos, reference sections in each chapter listing relevant review articles, and more From start to finish, Oral Precancer offers undergraduate students, clinicians, and professors an invaluable resource to minimise the morbidity and mortality of this most significant and life threatening of oral conditions. |
| anti-egfr antibody therapy: Basic Fundamentals of Drug Delivery , 2018-11-30 Basic Fundamentals of Drug Delivery covers the fundamental principles, advanced methodologies and technologies employed by pharmaceutical scientists, researchers and pharmaceutical industries to transform a drug candidate or new chemical entity into a final administrable drug delivery system. The book also covers various approaches involved in optimizing the therapeutic performance of a biomolecule while designing its appropriate advanced formulation. - Provides up-to-date information on translating the physicochemical properties of drugs into drug delivery systems - Explores how drugs are administered via various routes, such as orally, parenterally, transdermally or through inhalation - Contains extensive references and further reading for course and self-study |
| anti-egfr antibody therapy: Targeted Therapies in Breast Cancer Gw Sledge, George W. Sledge (Jr.), 2012-06 This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management. |
| anti-egfr antibody therapy: Therapeutic Antibody Engineering William R Strohl, Lila M Strohl, 2012-10-16 The field of antibody engineering has become a vital and integral part of making new, improved next generation therapeutic monoclonal antibodies, of which there are currently more than 300 in clinical trials across several therapeutic areas. Therapeutic antibody engineering examines all aspects of engineering monoclonal antibodies and analyses the effect that various genetic engineering approaches will have on future candidates. Chapters in the first part of the book provide an introduction to monoclonal antibodies, their discovery and development and the fundamental technologies used in their production. Following chapters cover a number of specific issues relating to different aspects of antibody engineering, including variable chain engineering, targets and mechanisms of action, classes of antibody and the use of antibody fragments, among many other topics. The last part of the book examines development issues, the interaction of human IgGs with non-human systems, and cell line development, before a conclusion looking at future issues affecting the field of therapeutic antibody engineering. - Goes beyond the standard engineering issues covered by most books and delves into structure-function relationships - Integration of knowledge across all areas of antibody engineering, development, and marketing - Discusses how current and future genetic engineering of cell lines will pave the way for much higher productivity |
| anti-egfr antibody therapy: CDC Yellow Book 2018: Health Information for International Travel Centers for Disease Control and Prevention CDC, 2017-04-17 THE ESSENTIAL WORK IN TRAVEL MEDICINE -- NOW COMPLETELY UPDATED FOR 2018 As unprecedented numbers of travelers cross international borders each day, the need for up-to-date, practical information about the health challenges posed by travel has never been greater. For both international travelers and the health professionals who care for them, the CDC Yellow Book 2018: Health Information for International Travel is the definitive guide to staying safe and healthy anywhere in the world. The fully revised and updated 2018 edition codifies the U.S. government's most current health guidelines and information for international travelers, including pretravel vaccine recommendations, destination-specific health advice, and easy-to-reference maps, tables, and charts. The 2018 Yellow Book also addresses the needs of specific types of travelers, with dedicated sections on: · Precautions for pregnant travelers, immunocompromised travelers, and travelers with disabilities · Special considerations for newly arrived adoptees, immigrants, and refugees · Practical tips for last-minute or resource-limited travelers · Advice for air crews, humanitarian workers, missionaries, and others who provide care and support overseas Authored by a team of the world's most esteemed travel medicine experts, the Yellow Book is an essential resource for travelers -- and the clinicians overseeing their care -- at home and abroad. |
| anti-egfr antibody therapy: Management of Cancer in the Older Patient E-Book Arash Naeim, David Reuben, Patricia Ganz, 2011-08-17 Management of Cancer in the Older Patient, by Drs. Arash Naeim, David Reuben, and Patricia Ganz, offers the help you need to effectively diagnose, refer, and manage cancer in geriatric patients. You’ll see how to provide effective cancer screening; refer your patients to the right oncologist; deal with comorbidities, frailties, and other complications; navigate end-of-life issues; and much more. A templated, user-friendly format makes it easy to find and apply the answers you need. See how to best manage geriatric cancer patients with help from leading specialists in both geriatrics and oncology Make informed decisions as to when to refer patients to specialists. Provide the supportive care your patients and their families need on issues such as such as mental health, pain, fatigue, nausea, insomnia. Be prepared to help cancer survivors navigate their after-treatment care including adjuvant therapy, side effects, second cancers, quality of life, and other concerns. Offer accurate guidance on ethical issues like competency, end of life, hospice, the role of the caregiver, and more. |
| anti-egfr antibody therapy: Rise and Fall of Epithelial Phenotype Pierre Savagner, 2007-07-05 Epithelial phenotype is a dynamic stage of differentiation that can be modulated during several physiological or pathological events. The rapid conversion to a mesenchymal-like phenotype is called an epithelial-mesenchymal transition (EMT). The Rise and Fall of Epithelial Phenotype is the first book to comprehensively introduce the concept of EMT. The first part of this volume describes main examples and models and explains their physiological relevance. These examples include hydra morphogenesis, gastrulation in mouse, drosophila and sea urchin, as well as neural crest cell migration and heart morphogenesis in vertebrates. Part two reviews in detail, specific EMT molecular pathways covering extracellular induction, transduction and transcription response and modulation of cell-cell adhesion structures. It emphasizes new specific pathways with potential medical applications. EMTs can also be linked to pathological events such as wound healing and cancer progression, as detailed in this section of the book. |
| anti-egfr antibody therapy: Cytotoxic Payloads for Antibody–Drug Conjugates David E Thurston, Paul J M Jackson, 2019-07-11 Antibody–drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and EU [i.e., ado-trastuzumab emtansine (KadcylaTM), brentuximab vedotin (AdcetrisTM), inotuzumab ozogamicin (BesponsaTM), gemtuzumab ozogamicin (MylotargTM) and moxetumomab pasudotox-tdfk (Lumoxiti®)] and over 70 others are in various stages of clinical development, with impressive interim results being reported for many. The technology is based on the concept of delivering a cytotoxic payload selectively to cancer cells by attaching it to an antibody targeted to antigens on the cell surfaces. This approach has several advantages including the ability to select patients as likely responders based on the presence of antigen on the surface of their cancer cells and a wider therapeutic index, given that ADC targeting enables a more efficient delivery of cytotoxic agents to cancer cells than can be achieved by conventional chemotherapy, thus minimising systemic toxicity. Although there are many examples of antibodies that have been developed for this purpose, along with numerous linker technologies used to attach the cytotoxic agent to the antibody, there is presently a relatively small number of payload molecules in clinical use. The purpose of this book is to describe the variety of payloads used to date, along with a discussion of their advantages and disadvantages and to provide information on novel payloads at the research stage that may be used clinically in the future. |
| anti-egfr antibody therapy: Theranostic Approach for Pancreatic Cancer Ganji Purnachandra Nagaraju, Sarfraz Ahmad, 2020-01-15 Theranostic Approach for Pancreatic Cancer modulates the biologic properties of stroma in pancreatic cancer by targeting the several chemotherapy resistance mechanisms to impede their malignant property through introducing new strategies and drugs for tackling the disease. It brings information about ongoing research as well as clinical data about pancreatic cancer and provides detailed descriptions about diagnostic and therapeutic options for easy understanding. This book discusses several topics related to pancreatic cancer such as stem cells, drug resistance and pancreatic tumor microenvironment, the latest developments in chemotherapy for metastatic cancer and chemoprevention, and epigenome as a therapeutic strategy. Additionally, it encompasses a discussion on theranostic clinical applications for personalized treatment and management of pancreatic cancer. The book is a valuable resource for cancer researchers, oncologists, and several members of the biomedical field who need to understand more about the diagnosis and treatment of pancreatic cancer. Provides information on the roadblocks of chemotherapy in patients with newly diagnosed and metastatic pancreatic cancer Discusses treatment options available currently as well as prospective options for the future Focuses especially on stroma, tumor microenvironment, stem cells, stellate cells, transcription factors, growth factors, and important signaling pathways as already tested types of treatment |
| anti-egfr antibody therapy: Prognostic Epigenetics , 2019-11-04 This volume provides comprehensive information on how mapping an individual's epigenome can be medically relevant and holds the potential to improve preventive medicine and precision therapeutics at an early-stage (prior to disease onset). In order to advance clinical adoption of the recently developed epigenetic approaches, it is necessary for translational scientists, clinicians, and students to gain a better understanding about epigenetic mechanisms that are associated with a particular disorder; and to be able to effectively identify biomarkers that can be applied in drug development and for better diagnosis and prognosis of diseases. Prognostic Epigenetics is the most-inclusive volume to-date specifically dedicated to epigenetic markers that have been developed for prognosis of diseases, recent advances in this field, the clinical implementation of this research, and the future outlook. |
| anti-egfr antibody therapy: Biologic Therapy of Cancer Vincent T. DeVita, Vincent T. DeVita (Jr.), Samuel Hellman, Steven A. Rosenberg, 1991 |
| anti-egfr antibody therapy: Management of Colorectal Cancer Harry Bleiberg, Phillipe Rougier, Hans-Joachim Wilke, 1997-09-17 Focusing on recent developments in the understanding and treatment of colorectal cancer, this detailed reference covers all aspects of the disease, with contributions from a strong international team of authors. * Includes chapters on genetics and molecular pathology * Provides a comprehensive overview of current and developing treatment strategies * Covers preoperative treatment and surgery, chemotherapy, biological therapies, and much more |
| anti-egfr antibody therapy: Cancer Immunotherapy Tyler J. Curiel, 2012-11-07 This work will provide a historical perspective on tumor immunotherapy, discuss fundamental mechanisms of failed tumor rejection, look at passive strategies to boost anti-tumor immunity, as well as have an in-depth look at active strategies to boost anti-tumor immunity. |
| anti-egfr antibody therapy: Antibodies in Diagnosis and Therapy Matzku, 2019-06-14 Monoclonal antibodies have had their impact on biomedical research for more than a decade. Beside their exuberant use as reagents, quite a number of diagnostic and therapeutic approaches have been followed and an impressive number of technological improvements, e.g., humanization, recombinant miniantibodies, have been elaborated to strengthen the principle. With respect to clinical applications, the first generation of antibody 'drugs' is yielding promising results while second and third generation antibody constructs are already underway. The book reviews the status of technological development and brings this into the perspective of clinical results. A rapidly growing amount of clinical data is collected in an expanding number of indications. Hence, the review of clinical study results has been grouped according to the fields of oncology and of chronic and acute inflammation. This book will be of interest to scientists working in the fields of oncology, immunology, internal medicine and clinical chemistry. |
| anti-egfr antibody therapy: Gastrointestinal Oncology Charles D. Blanke, Claus Rödel, Mark S. Talamonti, 2010-11-30 Gastrointestinal Oncology is an evidence-based, practical reference intended to assist in the diagnosis and management of patients with gastrointestinal malignancies. It is designed to be as user friendly as possible and is distinguished by the extremely practical, concrete nature of the information presented and by the multidisciplinary approach adopted. In addition to disease-oriented chapters spanning sites from the esophagus to the anus, non-anatomic subjects such as modern imaging techniques are also addressed. Translational science is supplied where useful in the decision-making process. All of the authors are internationally recognized experts. This book is an ideal resource for oncologists, surgeons, gastroenterologists, and primary-care providers looking for the latest and best information on how to deal with a wide variety of gastrointestinal neoplasms. |
| anti-egfr antibody therapy: Molecular Pathology in Clinical Practice Debra G.B. Leonard, 2016-02-02 This authoritative textbook offers in-depth coverage of all aspects of molecular pathology practice and embodies the current standard in molecular testing. Since the successful first edition, new sections have been added on pharmacogenetics and genomics, while other sections have been revised and updated to reflect the rapid advances in the field. The result is a superb reference that encompasses molecular biology basics, genetics, inherited cancers, solid tumors, neoplastic hematopathology, infectious diseases, identity testing, HLA typing, laboratory management, genomics and proteomics. Throughout the text, emphasis is placed on the molecular variations being detected, the clinical usefulness of the tests and important clinical and laboratory issues. The second edition of Molecular Pathology in Clinical Practice will be an invaluable source of information for all practicing molecular pathologists and will also be of utility for other pathologists, clinical colleagues and trainees. |
| anti-egfr antibody therapy: AACR 2018 Proceedings: Abstracts 1-3027 American Association for Cancer Research, 2018-04-10 |
| anti-egfr antibody therapy: AACR 2016: Abstracts 1-2696 American Association for Cancer Research (AACR), 2016-03-28 The AACR Annual Meeting is a must-attend event for cancer researchers and the broader cancer community. This year's theme, Delivering Cures Through Cancer Science, reinforces the inextricable link between research and advances in patient care. The theme will be evident throughout the meeting as the latest, most exciting discoveries are presented in every area of cancer research. There will be a number of presentations that include exciting new data from cutting-edge clinical trials as well as companion presentations that spotlight the science behind the trials and implications for delivering improved care to patients. This book contains abstracts 1-2696 presented on April 17-18, 2016, at the AACR Annual Meeting. |
| anti-egfr antibody therapy: Therapeutic Drug Monitoring Amitava Dasgupta, 2024-04-26 Therapeutic Drug Monitoring 2nd Edition is an updated reference on TDM analytical techniques in diverse clinical settings. This new edition reviews the exciting new developments in the area, including seven new chapters covering immunoassay design and applications, combined chromatographic techniques in therapeutic monitoring, drug monitoring in alternative specimens, pharmacogenomics of anticancer drugs, pharmacogenomics testing for patient management, selected antifungal agents, pharmacodynamic monitoring, and therapeutic drug monitoring of selected anticoagulants. All remaining chapters in the first edition were thoroughly revised and updated. Therapeutic Drug Monitoring 2nd Edition is the ideal reference for clinical pathologists, pharmacologists, and toxicologists involved with TDM. Scientists working in diagnostic companies, developing reagents for monitoring therapeutic drugs will also find relevant information in this book. - Includes new chapters covering antifungal, anticoagulant, and anticancer drugs monitoring - Discusses limitations of current immunoassays, new and sophisticated chromatographic techniques, the clinical effectiveness of newer antiretroviral agents, anticonvulsants and antidepressants - Provides full coverage of pharmacogenomics and personalized medicine, principles of pharmacokinetics and pharmacodynamics, and the application of biomarkers in TDM |
A multivalent biparatopic EGFR-targeting nanobody drug
As a clinically validated target, both small-molecule tyrosine kinase inhibitors and antibody-based drugs have been approved by regulatory agencies. Anti-EGFR antibody-drug conjugates …
Development of ABX-EGF, a fully human anti-EGF receptor …
To this end, using XenoMouseTM technology, ABX-EGF, a human IgG2 monoclonal antibody (mAb) specific to human EGFr, has been generated. ABX-EGF binds EGFr with high affinity (5 …
Overcoming the Hurdles: Surmounting Acquired Resistance to …
Mono-clonal antibodies such as cetuximab and panitumumab have proven to be efective against EGFR by blocking vital downstream signaling path-ways and inhibiting gene transcription and …
Amivantamab: A Potent Novel EGFR/c-MET Bispecific …
This review outlines the antibody design, mechanism of action, pharmacological profile, relevant preclinical and clinical studies, and safety and tolerability of amivantamab, a promising …
Amivantamab for the treatment of EGFR exon 20 insertion …
Introduction: Amivantamab is a monoclonal bispecific anti-EGFR-MET antibody that is the first targeted therapy to be approved for non-small cell lung cancer (NSCLC) patients harboring …
A cross-reactive pH-dependent EGFR antibody with improved …
Four mechanisms of action (MOA) have been reported to contribute to the antitumor activity of anti-EGFR antibodies: inhibiting ligand binding to block oncogenic signaling; triggering EGFR …
Immune biomarkers of anti-EGFR monoclonal antibody therapy
We review potential immunological biomarkers that affect mAb therapy in SCCHN patients, the implications of these findings and how they translate to the clinical scenario, which are critical …
The Role of Anti-EGFR Monoclonal Antibody in mCRC …
Epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) such as cetuximab and panitumumab combined with chemotherapy in patients with RAS wild-type mCRC can …
MEK116833 (CDRB436C2201) / NCT01750918 Inhibitor …
resistance to prior anti-EGFR therapy. The study design was intended to allow investigation of two doublet combinations (Dabrafenib (D)/ Panitumumab (P) and Trametinib (T)/Panitumumab …
Line by Line: Distinct Patterns of Anti-EGFR Antibody …
Dec 8, 2022 · In the articles that accompany this editorial, three in-teresting studies evaluate the molecular characteris-tics of acquired resistance to anti-EGFR antibody, focusing on different …
First-line treatment of anti-EGFR monoclonal antibody
Cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) represents a rst-line therapeutic standard for RAS/BRAF wild-type fi metastatic colorectal cancer (mCRC) patients.
Efficacy and safety of MCLA-129, an EGFR x c-MET bispecific …
• Osimertinib is a third-generation EGFR tyrosine kinase inhibitor approved as 1L therapy for EGFR ex19del and L858R NSCLC4 • MCLA-129 is a bispecific antibody targeting EGFR and …
Implementing anti-epidermal growth factor receptor (EGFR) …
Epidermal growth factor receptor (EGFR) inhibitors are valuable therapeutics in metastatic colorectal cancer (mCRC). Anti-EGFR monoclonal antibodies (MoAbs), such as cetuximab or …
monoclonal antibody therapy between G13D and mutant …
Cetuximab and pan-itumumab are anti-EGFR monoclonal antibodies (mAbs) that target the extracellular domain of EGFR, blocking activation of the MAPK pathway, and are important …
Monoclonal antibodies to target epidermal growth factor …
Effective anti-EGFR monoclonal antibodies compete with endogenous ligands, primarily EGF and transforming growth factor– , for receptor ligand-binding sites. Binding to EGFR blocks critical …
Brigatinib combined with anti-EGFR antibody overcomes
In the present study, we identify brigatinib to be effective against triple-mutation-harbouring cells in vitro and in vivo. Our original computational simulation demonstrates that brigatinib fits...
Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M …
harboring EGFR T790M and in trans C797S responds to combination therapy of first- and third-generation EGFR TKIs and shifts allelic configuration at resistance. J Thorac Oncol. …
Real-world use of anti-EGFR therapy in metastatic colorectal …
Here we report patterns of anti-EGFR therapy use in patients with mCRC diagnosed between 2013 and 2023.
Preclinical modeling of EGFR-specific antibody resistance: …
Anti-EGFR antibody-based therapy has been reported to mediate tumor regression by interrupting oncogenic signals and, more recently, by inducing antitumor immunological responses.
Efficacy and safety of cadonilimab plus anti-EGFR monoclonal …
Background: Cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, and Nimotuzumab, an anti-EGFR monoclonal antibody, have demonstrated effectiveness in treating persistent, re …
A multivalent biparatopic EGFR-targeting nanobody drug
As a clinically validated target, both small-molecule tyrosine kinase inhibitors and antibody-based drugs have been approved by regulatory agencies. Anti-EGFR antibody-drug conjugates (ADCs)...
Development of ABX-EGF, a fully human anti-EGF receptor …
To this end, using XenoMouseTM technology, ABX-EGF, a human IgG2 monoclonal antibody (mAb) specific to human EGFr, has been generated. ABX-EGF binds EGFr with high affinity (5 10 11 M), …
Overcoming the Hurdles: Surmounting Acquired Resistance to …
Mono-clonal antibodies such as cetuximab and panitumumab have proven to be efective against EGFR by blocking vital downstream signaling path-ways and inhibiting gene transcription and cell …
Amivantamab: A Potent Novel EGFR/c-MET Bispecific …
This review outlines the antibody design, mechanism of action, pharmacological profile, relevant preclinical and clinical studies, and safety and tolerability of amivantamab, a promising …
Amivantamab for the treatment of EGFR exon 20 insertion …
Introduction: Amivantamab is a monoclonal bispecific anti-EGFR-MET antibody that is the first targeted therapy to be approved for non-small cell lung cancer (NSCLC) patients harboring EGFR …
A cross-reactive pH-dependent EGFR antibody with improved …
Four mechanisms of action (MOA) have been reported to contribute to the antitumor activity of anti-EGFR antibodies: inhibiting ligand binding to block oncogenic signaling; triggering EGFR …
Immune biomarkers of anti-EGFR monoclonal antibody therapy
We review potential immunological biomarkers that affect mAb therapy in SCCHN patients, the implications of these findings and how they translate to the clinical scenario, which are critical to …
The Role of Anti-EGFR Monoclonal Antibody in mCRC …
Epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) such as cetuximab and panitumumab combined with chemotherapy in patients with RAS wild-type mCRC can alleviate …
MEK116833 (CDRB436C2201) / NCT01750918 Inhibitor …
resistance to prior anti-EGFR therapy. The study design was intended to allow investigation of two doublet combinations (Dabrafenib (D)/ Panitumumab (P) and Trametinib (T)/Panitumumab (P)), in …
Line by Line: Distinct Patterns of Anti-EGFR Antibody …
Dec 8, 2022 · In the articles that accompany this editorial, three in-teresting studies evaluate the molecular characteris-tics of acquired resistance to anti-EGFR antibody, focusing on different …
First-line treatment of anti-EGFR monoclonal antibody
Cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) represents a rst-line therapeutic standard for RAS/BRAF wild-type fi metastatic colorectal cancer (mCRC) patients.
Efficacy and safety of MCLA-129, an EGFR x c-MET bispecific …
• Osimertinib is a third-generation EGFR tyrosine kinase inhibitor approved as 1L therapy for EGFR ex19del and L858R NSCLC4 • MCLA-129 is a bispecific antibody targeting EGFR and c-MET, with …
Implementing anti-epidermal growth factor receptor …
Epidermal growth factor receptor (EGFR) inhibitors are valuable therapeutics in metastatic colorectal cancer (mCRC). Anti-EGFR monoclonal antibodies (MoAbs), such as cetuximab or …
monoclonal antibody therapy between G13D and mutant …
Cetuximab and pan-itumumab are anti-EGFR monoclonal antibodies (mAbs) that target the extracellular domain of EGFR, blocking activation of the MAPK pathway, and are important …
Monoclonal antibodies to target epidermal growth factor …
Effective anti-EGFR monoclonal antibodies compete with endogenous ligands, primarily EGF and transforming growth factor– , for receptor ligand-binding sites. Binding to EGFR blocks critical …
Brigatinib combined with anti-EGFR antibody overcomes
In the present study, we identify brigatinib to be effective against triple-mutation-harbouring cells in vitro and in vivo. Our original computational simulation demonstrates that brigatinib fits...
Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M …
harboring EGFR T790M and in trans C797S responds to combination therapy of first- and third-generation EGFR TKIs and shifts allelic configuration at resistance. J Thorac Oncol. …
Real-world use of anti-EGFR therapy in metastatic colorectal …
Here we report patterns of anti-EGFR therapy use in patients with mCRC diagnosed between 2013 and 2023.
Preclinical modeling of EGFR-specific antibody resistance: …
Anti-EGFR antibody-based therapy has been reported to mediate tumor regression by interrupting oncogenic signals and, more recently, by inducing antitumor immunological responses.
Efficacy and safety of cadonilimab plus anti-EGFR monoclonal …
Background: Cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, and Nimotuzumab, an anti-EGFR monoclonal antibody, have demonstrated effectiveness in treating persistent, re-current, …
